News

The company sees the latest trial results reinforcing its ambitions to rapidly develop a portfolio of medicines for people with obesity, diabetes and cardiovascular disease.

Find insight on Novo Nordisk, Roche Holding, IHH Healthcare and more in the latest Market Talks covering Health Care.

Novo Nordisk (NYSE:NVO) is considering acquisitions to strengthen its weight-loss drug pipeline and expand into related therapeutic areas as competition increases, Chief Executive Mike Doustdar said on Tuesday. Speaking to CNBC’s Squawk Box Europe, Doustdar said the Danish pharmaceutical company was examining opportunities to address gaps in its portfolio, including acquiring medicines that could complement or outperform treatments developed internally.

All three major US stock indexes were up in late-morning trading Monday, as oil prices and Treasury

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Shares in the company fell more than 4% as its CEO laid out plans for new blockbuster drugs in the next few years.

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports.

Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.

Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which sees structural changes supporting stronger European returns.

The approval for its generic version of Novo Nordisk’s blockbuster drug advances its efforts to build a portfolio of GLP-1 medicines.

The Federal Reserve raised interest rates for the first time in three years, reversing cuts it made last year and implicitly countering the White House’s position that inflation isn’t a concern. Treasury yields moved higher after Fed Chairman Kevin Warsh began his post-decision press conference.

Sept 16 (Reuters) - Novo Nordisk has partnered with Anthropic to use the AI giant's Claude models to speed up discovery and development of new medicines, the companies said on Wednesday.

By Richa Naidu LONDON, Sept 16 (Reuters) - Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said,

The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.

Novo Nordisk is shortening its name as part of an effort to boost its appeal to consumers in the obesity drug market, where the Danish drugmaker...

One date in the next decade is quietly doing all the work in Wall Street’s newest bear case.

Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.

Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook

Investing.com -- JPMorgan revealed Friday that it has started coverage of Hims & Hers Health at Neutral, setting a December 2027 price target of $32 as it weighs the direct-to-consumer health platform's rapid growth against execution risks in its shift to branded weight-loss drugs.

Markets are bracing for Friday's CPI data after a brutal week of selling across stocks, bonds, and crypto, and Wall Street analysts are already reshuffling their ratings on names like Dell, Shopify, Novo Nordisk, and Fortinet before the dust settles.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.03%, and the actively tr

The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.

Investing.com -- Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell from Hold and cut its price target by 9% to 265 Danish crowns from 290 crowns, flagging persisting concerns over the company’s growth trajectory. The stock fell more than 3% in Copenhagen trading Thursday.

Find insight on Novo Nordisk, Innovent Biologics, Ramsay Health Care and more in the latest Market Talks covering Health Care.

Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.

By Tharuniyaa Lakshmi and Utkarsh Hathi Aug 25 (Reuters) - European shares rose on Tuesday as investors took comfort from a softer-than-feared U.S. sanctions package on Iran and falling oil prices,

The study will run into 2028, testing two low doses of Wegovy, and follows the company disclosing recently that uptake of the pill had been particularly strong for its lowest doses across self-paying patients.

Investing.com -- Hims & Hers Chief Executive Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit concerning its data sharing practices in an interview that aired Tuesday on CNBC's "Squawk Box."